Modulation of 5-fluorouracil catabolism in isolated rat hepatocytes with enhancement of 5-fluorouracil glucuronide formation
- PMID: 3965128
Modulation of 5-fluorouracil catabolism in isolated rat hepatocytes with enhancement of 5-fluorouracil glucuronide formation
Abstract
The catabolism of 5-fluorouracil (FUra), which accounts for 90% of the elimination of this antimetabolite in vivo, has recently been characterized in freshly isolated rat hepatocytes in suspension using a highly specific high-performance liquid chromatographic methodology. The present study evaluates the effect of thymine and uracil, which are thought to be catabolized by the same enzymes as FUra, on the metabolism and transmembrane distribution of FUra in isolated rat hepatocytes. Following simulataneous exposure of cells for 5 min to 30 microM [6-3H]FUra and increasing concentrations of either thymine or uracil, dihydrofluorouracil (FUH2) levels decreased in a concentration-dependent manner, and the concentration determined for 50% inhibition of FUra catabolism was 8.0 +/- 0.3 (S.D.) and 67.8 +/- 15.6 microM for thymine and uracil, respectively. Analysis of intracellular and extracellular 3H from 1 min to 2 hr after simultaneous incubation of the hepatocytes with 30 microM FUra and thymine (or uracil) in a 1:7 molar ratio resulted in a decrease of intracellular and extracellular FUH2 and alpha-fluoro-beta-alanine (FBAL), while alpha-fluoro-beta-ureidopropionic acid (FUPA) was enhanced. Unmetabolized FUra (not detected in the absence of thymine or uracil) was detected intracellularly in the presence of thymine or uracil and was accompanied by the appearance of a novel metabolite, preliminarily identified as a glucuronide of the FUra base which reached intracellular levels of 44 +/- 9.76 and 27.45 +/- 1.35 microM in the presence of thymine or uracil, respectively, within 1 hr. This metabolite, which penetrates the cell membrane only slowly, accounted for approximately 60% of the intracellular 3H in the presence of 300 microM FUra and 2 mM thymine, whereas FUra catabolism was inhibited by more than 99% under these conditions. The formation of FUra anabolites was insignificant in the presence of thymine and uracil, and incorporation of FUra into RNA was not enhanced. The lack of anabolism of FUra in isolated hepatocytes exposed to either high initial concentrations of FUra or high intracellular FUra concentrations resulting from modulation (inhibition) of FUra catabolism is consistent with the clinical observation of minimal hepatotoxicity with FUra, despite exposure of the liver to high blood levels. These studies indicate that thymine is a more potent modulator of FUra catabolism in hepatocytes than is uracil. Further studies are needed to clarify the biological importance of the glucuronide of the base FUra which accumulates intracellularly as the concentration of FUra increases within the hepatocytes.
Similar articles
-
Evidence from rat hepatocytes of an unrecognized pathway of 5-fluorouracil metabolism with the formation of a glucuronide derivative.Cancer Res. 1985 Jun;45(6):2450-5. Cancer Res. 1985. PMID: 3986786
-
Effect of 5-diazouracil on the catabolism of circulating pyrimidines in rat liver and kidneys.Cancer Res. 1986 Nov;46(11):5576-81. Cancer Res. 1986. PMID: 3756903
-
Dihydrofluorouracil, a fluorouracil catabolite with antitumor activity in murine and human cells.Cancer Res. 1985 Oct;45(10):4900-3. Cancer Res. 1985. PMID: 3928143
-
Clinical pharmacokinetics of fluorouracil and folinic acid.Semin Oncol. 1992 Apr;19(2 Suppl 3):82-92. Semin Oncol. 1992. PMID: 1557660 Review.
-
Metabolism of pyrimidine analogues and their nucleosides.Pharmacol Ther. 1990;48(2):189-222. doi: 10.1016/0163-7258(90)90080-l. Pharmacol Ther. 1990. PMID: 2293239 Review.
Cited by
-
Cellular pharmacology of fluorinated pyrimidines in vivo in man.Invest New Drugs. 1989 Apr;7(1):13-25. doi: 10.1007/BF00178188. Invest New Drugs. 1989. PMID: 2661480 Review.
-
Effect of coadministered uridine on intestinal first-pass metabolism of 5'-deoxy-5-fluorouridine in conscious rats--an evaluation by method of portal-systemic concentration difference.Pharm Res. 1998 Jul;15(7):1007-11. doi: 10.1023/a:1011917824836. Pharm Res. 1998. PMID: 9688052
-
Clinical pharmacology of 5-fluorouracil.Clin Pharmacokinet. 1989 Apr;16(4):215-37. doi: 10.2165/00003088-198916040-00002. Clin Pharmacokinet. 1989. PMID: 2656050 Review.
-
Validation of an isocratic HPLC method to detect 2-fluoro-beta-alanine for the analysis of dihydropyrimidine dehydrogenase activity.J Chromatogr B Analyt Technol Biomed Life Sci. 2010 Jul 1;878(21):1889-92. doi: 10.1016/j.jchromb.2010.05.010. Epub 2010 May 19. J Chromatogr B Analyt Technol Biomed Life Sci. 2010. PMID: 20570578 Free PMC article.
-
Pharmacokinetic drug interactions of commonly used anticancer drugs.Clin Pharmacokinet. 1986 May-Jun;11(3):223-35. doi: 10.2165/00003088-198611030-00004. Clin Pharmacokinet. 1986. PMID: 2426030 Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources